The NKI Center for Early Diagnostics and Urimon have launched a collaboration to develop new methods that can detect prostate cancer through a urine test. By combining their expertise, both parties aim to contribute to better and less invasive early detection of prostate cancer.
Biobank
Urimon focuses on innovative technologies that provide health insights through urine tests, while the NKI Center for Early Diagnosis specializes in rapid diagnostics and scientific research for early cancer detection. This joint project involves an exchange of urine samples from men with and without prostate cancer. These men volunteered to be included in the biobank of the NKI Center for Early Diagnosis and made their samples available for scientific research. The data and urine samples from the biobank provide valuable data to improve diagnostic methods for earlier cancer detection.
Dr. Doreth Bhairosing, Research Coordinator at the NKI Center for Early Diagnostics: “By combining knowledge and technology, we can take faster steps toward less invasive and more reliable early detection of prostate cancer. If we can detect prostate cancer earlier, we can use less intensive treatments and increase the chance of recovery.”
Dr. Johan de Rooij, Scientific Lead of the Urimon research: “The collaboration with the NKI Center for Early Diagnostics, providing high-quality biosamples and expertise, brings the validation of our Urimon method for early disease detection significantly closer and accelerates its availability for patients.”
Ambition
This collaboration aligns with the shared ambition to drive innovation in early cancer detection and make a meaningful difference for the patients of tomorrow.
